Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
ConditionLung Adenocarcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-79
SponsorShanghai Pulmonary Hospital, Shanghai, China
About this trial
This study aims to evaluate the non-inferiority in recurrence-free survival and overall survival of segmentectomy compared with lobectomy in patients with lung adenocarcinoma ≤ 2 cm with micropapillary and solid subtype negative by intraoperative frozen sections.
Eligibility criteria
Qualifiers
Patient aged 20-79 years old, both male or female;
Tumor size <= 2cm on preoperative CT scan;
Peripheral solitary nodule or the associated lesion is MIA or less invasive lesion;
Preoperative CT indicated that the nodules were non-pure glass nodules (consolidation to tumor ratio >= 0.25);
Disqualifiers
Radiological pure ground glass nodules (consolidation to tumor ratio < 0.25);
The nodule is close to the lung hilus and is unable to perform segmentectomy;
Intraoperative frozen section confirmed with micropapillary and solid subtype positive (> 5%);
Intraoperative frozen section confirmed adenocarcinoma in situ and minimally invasive adenocarcinoma;
Trial design
Treatments tested in this trial
- Segmentectomy
- Lobectomy
Treatment groups
690 Participants
are divided into 2 treatment groupsLocations
14Anhui Chest Hospital HefeiAnhui, China
The First Affiliated Hospital of University of Science and Technology of China HefeiAnhui, China
Nanyang Central Hospital NanyangHenan, China
Affiliated Hospital of Nantong University226001, NantongJiangsu, China
Sponsors and collaborators
Shanghai Pulmonary Hospital, Shanghai, China
Lead sponsor
Source ClinicalTrials.gov